A breakthrough treatment raises hopes for rare bone disease. Palovarotene (Sohonos) has been recently approved by the FDA as a retinoid indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare progressive genetic disease effecting one in a million individuals. This first and only treatment is able to effectively reduce the formation of new abnormal bone in soft and connective tissues.